Clinical parameter
|
N
|
Early recurrence
|
Late recurrence
|
---|
Pvalue
|
HR (95% CI)
|
N (event)
|
Pvalue
|
HR (95% CI)
|
N (event)
|
---|
HER2
|
pos. vs. neg.
|
743
|
0.1378
|
1.36 (0.91 - 2.04)
|
207
|
0.7788
|
1.10 (0.57 - 2.13)
|
80
|
ER
|
pos. vs. neg.
|
743
|
0.0048
|
0.63 (0.46 - 0.87)
|
207
|
0.5023
|
1.19 (0.72 - 1.97)
|
80
|
PR
|
pos. vs. neg.
|
743
|
0.0004
|
0.61 (0.46 - 0.80)
|
207
|
0.1027
|
1.45 (0.93 - 2.28)
|
80
|
TNBC
|
TN vs. others
|
743
|
0.0031
|
1.77 (1.21 - 2.59)
|
207
|
0.0974
|
0.61 (0.34 - 1.10)
|
80
|
Tumor size
|
≥2 cm vs. <2 cm
|
456
|
0.0008
|
1.91 (1.31 - 2.78)
|
114
|
0.3184
|
1.29 (0.78 - 2.12)
|
67
|
Grade
|
Grade 3 vs. others
|
438
|
0.0038
|
1.87 (1.22 - 2.84)
|
110
|
0.0692
|
0.60 (0.35 - 1.04)
|
61
|
Age
|
≥50 vs. <50
|
457
|
0.9933
|
1.00 (0.69 - 1.44)
|
114
|
0.1144
|
0.67 (0.41 - 1.10)
|
66
|
- CI: confidence interval; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; HR, hazard ratio; PR: progesterone receptor; TNBC: triple-negative breast cancer.